Viruses traverse the human proteome through peptide interfaces that can be biomimetically leveraged for drug discovery
We present a drug design strategy based on structural knowledge of protein-protein interfaces selected through virus-host coevolution and translated into highly potential small molecules. This approach is grounded on Vinland, the most comprehensive atlas of virus-human protein-protein interactions with annotation of interacting domains. From this inspiration, we identified small viral protein domains responsible for interaction with human proteins. These peptides form a library of new chemical entities used to screen for replication modulators of several pathogens. As a proof of concept, a peptide from a KSHV protein, identified as an inhibitor of influenza virus replication, was translated into a small molecule series with low nanomolar antiviral activity. By targeting the NEET proteins, these molecules turn out to be of therapeutic interest in a nonalcoholic steatohepatitis mouse model with kidney lesions. This study provides a biomimetic framework to design original chemistries targeting cellular proteins, with indications going far beyond infectious diseases.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:121 |
---|---|
Enthalten in: |
Proceedings of the National Academy of Sciences of the United States of America - 121(2024), 5 vom: 30. Jan., Seite e2308776121 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Meyniel-Schicklin, Laurène [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomimetism |
---|
Anmerkungen: |
Date Completed 24.01.2024 Date Revised 04.02.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1073/pnas.2308776121 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367433184 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM367433184 | ||
003 | DE-627 | ||
005 | 20240204232004.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240123s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1073/pnas.2308776121 |2 doi | |
028 | 5 | 2 | |a pubmed24n1280.xml |
035 | |a (DE-627)NLM367433184 | ||
035 | |a (NLM)38252831 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Meyniel-Schicklin, Laurène |e verfasserin |4 aut | |
245 | 1 | 0 | |a Viruses traverse the human proteome through peptide interfaces that can be biomimetically leveraged for drug discovery |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.01.2024 | ||
500 | |a Date Revised 04.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a We present a drug design strategy based on structural knowledge of protein-protein interfaces selected through virus-host coevolution and translated into highly potential small molecules. This approach is grounded on Vinland, the most comprehensive atlas of virus-human protein-protein interactions with annotation of interacting domains. From this inspiration, we identified small viral protein domains responsible for interaction with human proteins. These peptides form a library of new chemical entities used to screen for replication modulators of several pathogens. As a proof of concept, a peptide from a KSHV protein, identified as an inhibitor of influenza virus replication, was translated into a small molecule series with low nanomolar antiviral activity. By targeting the NEET proteins, these molecules turn out to be of therapeutic interest in a nonalcoholic steatohepatitis mouse model with kidney lesions. This study provides a biomimetic framework to design original chemistries targeting cellular proteins, with indications going far beyond infectious diseases | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a biomimetism | |
650 | 4 | |a chemoinformatics | |
650 | 4 | |a interactomics | |
650 | 4 | |a kidney | |
650 | 4 | |a viruses | |
650 | 7 | |a Proteome |2 NLM | |
650 | 7 | |a Peptides |2 NLM | |
700 | 1 | |a Amaudrut, Jérôme |e verfasserin |4 aut | |
700 | 1 | |a Mallinjoud, Pierre |e verfasserin |4 aut | |
700 | 1 | |a Guillier, Fabrice |e verfasserin |4 aut | |
700 | 1 | |a Mangeot, Philippe E |e verfasserin |4 aut | |
700 | 1 | |a Lines, Laetitia |e verfasserin |4 aut | |
700 | 1 | |a Aublin-Gex, Anne |e verfasserin |4 aut | |
700 | 1 | |a Scholtes, Caroline |e verfasserin |4 aut | |
700 | 1 | |a Punginelli, Claire |e verfasserin |4 aut | |
700 | 1 | |a Joly, Stéphane |e verfasserin |4 aut | |
700 | 1 | |a Vasseur, Florence |e verfasserin |4 aut | |
700 | 1 | |a Manet, Evelyne |e verfasserin |4 aut | |
700 | 1 | |a Gruffat, Henri |e verfasserin |4 aut | |
700 | 1 | |a Henry, Thomas |e verfasserin |4 aut | |
700 | 1 | |a Halitim, Farès |e verfasserin |4 aut | |
700 | 1 | |a Paparin, Jean-Laurent |e verfasserin |4 aut | |
700 | 1 | |a Machin, Peter |e verfasserin |4 aut | |
700 | 1 | |a Darteil, Raphaël |e verfasserin |4 aut | |
700 | 1 | |a Sampson, Diane |e verfasserin |4 aut | |
700 | 1 | |a Mikaelian, Ivan |e verfasserin |4 aut | |
700 | 1 | |a Lane, Lydie |e verfasserin |4 aut | |
700 | 1 | |a Navratil, Vincent |e verfasserin |4 aut | |
700 | 1 | |a Golinelli-Cohen, Marie-Pierre |e verfasserin |4 aut | |
700 | 1 | |a Terzi, Fabiola |e verfasserin |4 aut | |
700 | 1 | |a André, Patrice |e verfasserin |4 aut | |
700 | 1 | |a Lotteau, Vincent |e verfasserin |4 aut | |
700 | 1 | |a Vonderscher, Jacky |e verfasserin |4 aut | |
700 | 1 | |a Meldrum, Eric C |e verfasserin |4 aut | |
700 | 1 | |a de Chassey, Benoit |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Proceedings of the National Academy of Sciences of the United States of America |d 1915 |g 121(2024), 5 vom: 30. Jan., Seite e2308776121 |w (DE-627)NLM000008982 |x 1091-6490 |7 nnns |
773 | 1 | 8 | |g volume:121 |g year:2024 |g number:5 |g day:30 |g month:01 |g pages:e2308776121 |
856 | 4 | 0 | |u http://dx.doi.org/10.1073/pnas.2308776121 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 121 |j 2024 |e 5 |b 30 |c 01 |h e2308776121 |